转自双语君
12月31日，国务院联防联控机制发布，国药集团(tuan)中(zhong)国生物(wu)新冠灭活(huo)疫(yi)苗已获得国家药监局批(pi)准附条件上市。
China announced it has granted conditional market approval for its first COVID-19 vaccine during a Thursday news conference.
The vaccine, developed by State-owned Sinopharm, was approved by China's top drug regulator on Wednesday night, said Chen Shifei, deputy head of the National Medical Products Administration.
国(guo)(guo)家(jia)药(yao)(yao)(yao)品监督管理局副(fu)局长(zhang)陈时(shi)飞称，国(guo)(guo)家(jia)药(yao)(yao)(yao)监局已于30日附条(tiao)件批准了国(guo)(guo)药(yao)(yao)(yao)集团中国(guo)(guo)生物北京公(gong)司新冠病毒(du)灭活疫苗注册申请。
已有数(shu)据(ju)显(xian)示，疫(yi)苗(miao)保护率为79.34%，实现安(an)全性、有效(xiao)性、可及性、可负担性的统一(yi)，达到世(shi)界(jie)卫生(sheng)组织(zhi)及国(guo)家药监局相关(guan)标准要求。后续，疫(yi)苗(miao)免疫(yi)的持久性和保护效(xiao)果(guo)还需持续观察(cha)。
The vaccine is generally safe and has a 79.34 percent efficacy rate according to clinical results released by the company on Wednesday. Strict supervision will continue to be carried out over the vaccine after its approval to ensure its safety and quality, Chen said.
这一成果来之不(bu)易，中国疫苗上市为(wei)全球战胜(sheng)疫情(qing)注入信(xin)心，也(ye)为(wei)疫苗成为(wei)全球公共(gong)产品提供有力(li)支(zhi)撑(cheng)。
